1-{trans-4-[(2-phenylethyl)amino]cyclohexyl}-3-(pyridin-3-ylmethyl)urea | 1333939-77-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-{trans-4-[(2-phenylethyl)amino]cyclohexyl}-3-(pyridin-3-ylmethyl)urea
• CAS: 1333939-77-7
• 化学式: C₂₁H₂₈N₄O
• 分子量: 352.48
• InChiKey: GDTXODTYMPVHLF-MXVIHJGJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.02
• 重原子数：
  26.0
• 可旋转键数：
  7.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  66.05
• 氢给体数：
  3.0
• 氢受体数：
  3.0

文献信息

• COMPOUNDS AND THERAPEUTIC USES THEREOF
  申请人：Willardsen J. Adam

  公开号：US20120329786A1

  公开（公告）日：2012-12-27

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders.

  本发明涉及化合物、药物组合物和方法，用于治疗癌症、全身或慢性炎症、类风湿性关节炎、糖尿病、肥胖症、T细胞介导的自身免疫性疾病、缺血以及与这些疾病和疾病相关的其他并发症。
• THERAPEUTIC AND DIAGNOSTIC METHODS
  申请人：Fleischer Tracey C.

  公开号：US20160367541A1

  公开（公告）日：2016-12-22

  The invention relates to methods of treating diseases, particularly cancers, that respond favorably to the inhibition of Nicotinamide phosphoribosyltransferase (Nampt); it also relates to therapeutic methods that utilize Nampt inhibitors in combination with NAD biosynthesis precursors to intentionally kill cancer cells while limiting or minimizing toxicity to normal host cells; and it relates to methods of identifying cancers that will be most responsive to treatment with Nampt inhibitors, particularly when administered in combination with nicotinic acid.
• US8912184B1
  申请人：——

  公开号：US8912184B1

  公开（公告）日：2014-12-16